ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.53
-0.50%
Dow Jones
44,544.66
-0.75%
US Dollar vs MXN
21.1849
3.42%
Brent Oil
76.285
-0.09%
Bitcoin
94,200.65
-3.58%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE

  6. Molecular Partners Ag (0QXX) Cotización

Molecular Partners Ag

Molecular Partners Ag (0QXX)

LSE
25.20
0.00
(0.00%)
Cerrado 03 Febrero 10:30AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
25.20
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
104
0.00 Rango del Día 0.00
25.20 Rango de 52 semanas 25.20
Capitalización de Mercado [m]
916.121M
Precio Anterior
25.20
Precio de Apertura
-
Hora
87
@
4.845
(O)
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
486
Acciones en circulación
36,354,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.48
Beneficio por acción (BPA)
-1.71
turnover
7.04M
Beneficio neto
-61.98M

Acerca de Molecular Partners Ag

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.molecularpartners.com
Sede
Schlieren, Che
Fundado
-
Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QXX. The last closing price for Molecular Partners was CHF25.20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25.20 to CHF 25.20.

Molecular Partners currently has 36,354,000 shares in issue. The market capitalisation of Molecular Partners is CHF916.12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -2.48.

0QXX Últimas noticias

Más noticias

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference Radio-DARPin MP0712 against DLL3, in...

12 Enero 2025
UK Regulatory

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer New agreement enables both companies to fuel a broad and innovative pipeline of...

12 Enero 2025
UK Regulatory

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE...

17 Diciembre 2024
UK Regulatory

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 MP0533 phase 1/2a dose escalation study...

08 Diciembre 2024
UK Regulatory

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 Preclinical proof-of-concept data supports the...

07 Noviembre 2024
UK Regulatory

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall...

05 Noviembre 2024
UK Regulatory

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy...

31 Octubre 2024
UK Regulatory

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art...

25 Octubre 2024
UK Regulatory

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs;...

22 Octubre 2024
UK Regulatory

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with...

22 Octubre 2024
UK Regulatory
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10025.225.225.2825.2DE
40025.225.225.244525.2DE
120025.225.225.248625.2DE
260025.225.225.238725.2DE
520025.225.225.235525.2DE
1560025.225.225.2601325.2DE
2600025.225.225.2517125.2DE

0QXX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Molecular Partners?
El precio actual de las acciones de Molecular Partners es CHF 25.20
¿Cuántas acciones de Molecular Partners están en circulación?
Molecular Partners tiene 36,354,000 acciones en circulación
¿Cuál es la capitalización de mercado de Molecular Partners?
La capitalización de mercado de Molecular Partners es CHF 916.12M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Molecular Partners?
Molecular Partners ha negociado en un rango de CHF 25.20 a CHF 25.20 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Molecular Partners?
El ratio precio/beneficio de Molecular Partners es -2.48
¿Cuál es el ratio de efectivo a ventas de Molecular Partners?
El ratio de efectivo a ventas de Molecular Partners es 21.8
¿Cuál es la moneda de reporte de Molecular Partners?
Molecular Partners presenta sus resultados financieros en CHF
¿Cuál es el último ingresos anual de Molecular Partners?
El último ingresos anual de Molecular Partners es CHF 7.04M
¿Cuál es el último beneficio anual de Molecular Partners?
El último beneficio anual de Molecular Partners es CHF -61.98M
¿Cuál es la dirección registrada de Molecular Partners?
La dirección registrada de Molecular Partners es WAGISTRASSE 14, SCHLIEREN, 8952
¿Cuál es la dirección del sitio web de Molecular Partners?
La dirección del sitio web de Molecular Partners es www.molecularpartners.com
¿En qué sector industrial opera Molecular Partners?
Molecular Partners opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AIQAiq Limited
4.00p
(33.33%)
37.88k
INSPInspirit Energy Holdings Plc
0.0036p
(28.57%)
1.43B
ALKAlkemy Capital Investments Plc
175.00p
(27.27%)
176.27k
KNBKanabo Group Plc
1.00p
(25.00%)
461.04k
TCFTheracryf Plc
1.125p
(25.00%)
6.72M
MET1Metals One Plc
0.275p
(-35.29%)
16.2M
PPSProton Motor Power Systems Plc
0.175p
(-22.22%)
848.7k
SYMESupply@me Capital Plc
0.0025p
(-19.35%)
372.49M
CGNRConroy Gold & Natural Resources Plc
2.15p
(-18.87%)
739.53k
ONCOncimmune Holdings Plc
10.40p
(-16.47%)
1.19M
INSPInspirit Energy Holdings Plc
0.0036p
(28.57%)
1.43B
NTVONativo Resources Plc
0.0018p
(-5.26%)
1.41B
MSMNMosman Oil And Gas Limited
0.041p
(10.81%)
1.22B
TRPTower Resources Plc
0.0295p
(0.00%)
691.76M
SYMESupply@me Capital Plc
0.0025p
(-19.35%)
372.49M

Discusión

Ver feed completo
BottomBounce BottomBounce 5 minutos hace
$BLDP Ballard Power Systems Inc. engages in the design, development, manufacture, sale, and service of proton exchange membrane (PEM) fuel cell products. The company offers its products for power product comprising for bus, truck, rail, marine, stationary, and emerging market, such as material handl
BLDP
BottomBounce BottomBounce 6 minutos hace
$BLDP Ballard Power Systems Inc. engages in the design, development, manufacture, sale, and service of proton exchange membrane (PEM) fuel cell products. The company offers its products for power product comprising for bus, truck, rail, marine, stationary, and emerging market, such as material handl
BLDP
BottomBounce BottomBounce 6 minutos hace
$PLUG Plug Power Inc. develops hydrogen and fuel cell product solutions in North America, Europe, Asia, and internationally. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenSure, a stationar
PLUG
BottomBounce BottomBounce 6 minutos hace
$PLUG Plug Power Inc. develops hydrogen and fuel cell product solutions in North America, Europe, Asia, and internationally. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenSure, a stationar
PLUG
europa7 europa7 6 minutos hace
Greyscale AI Leverages Prove AI on Hedera for Reliable Data Governance
https://proveai.com/blog/greyscaleleveragesproveai

A Closer Look at Greyscale AI’s Use Case

"...Greyscale AI applies advanced machine learning and x-ray imaging to identify contaminants in the
HBARUSD
BottomBounce BottomBounce 7 minutos hace
$NIO NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; P
NIO
arizona1 arizona1 7 minutos hace
No one voted for Donnie Convict to make Canada one of our enemies. Their people are mostly white so it's only Mexico and the brown people you idiots were rooting to screw over.
BottomBounce BottomBounce 7 minutos hace
$NIO NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; P
NIO
BottomBounce BottomBounce 8 minutos hace
https://finance.yahoo.com/news/tilray-brands-inc-tlry-among-034930975.html $DEO
DEO
BottomBounce BottomBounce 9 minutos hace
https://finance.yahoo.com/news/tilray-brands-inc-tlry-among-034930975.html $STZ
STZ
facts_matter14 facts_matter14 9 minutos hace
TriCasacde Inc WILL present in the booth WITH Quectel.
Seems like a pretty clear and definitive statement, made over and over, and over.

Too bad it was total manipulation, which included the photoshopped TriCascade Inc logo, onto the trade show booth map, intended to reel in th
SRMX
arizona1 arizona1 9 minutos hace
I knew Reeves was an environmentalist but not much else about him.
Researchfyi Researchfyi 10 minutos hace
You got $2 bucks? Mega Millions, try 7, 10, 12, 32, 40. Mega Ball 18.

When those get picked. You are rich.
LQMT
3331 3331 12 minutos hace
SAVVY INVESTORS RECOGNIZE BIEL IS AN APPLE/AMAZON TYPE of INVESTMENT (in terms of ROI)

When BIEL hits .01, the return on investment for a .0003 buy will be greater than the 10 year ROI (>3,000%) for Amazon and Apple.

BIEL can hit copper in IN THE BLINK OF AN EYE, as $1.
ENDV QUBT SERV
arizona1 arizona1 13 minutos hace
One of the BIG orders signed on DAY ONE was "drill, baby drill"

Gas prices are going up and the oil companies have no intention to start drilling new land. They have thousands of leases and 25 million acres they could have been drilling on for decades. They're divesting into clean e
hap0206 hap0206 15 minutos hace
Apparently, it is drugs -- do not know the details
firebag1 firebag1 16 minutos hace
we havent had a liberal govt for the past 8 years lol it was a far left leaning socialist marxist regime that the traitor singh propped up.. the canadians now realize what an ndp govt looks like - maybe you should listen to Jordan Peterson and other scholars cause my dear me thinks you are the one
facts_matter14 facts_matter14 18 minutos hace
What part of SCAM is not understood about POSRMX?

Why do you think it’s down 99% since 2-12-21?

Why do you think I.Va disappeared?

Why do you think E-Bike was delayed a year?

Why was SKIQ still on the website in 2022, after being declared “
BURU MDCN

Su Consulta Reciente

LSE
0QXX
Molecular Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios